Scinai Immunotherapeutics Ltd. financial data

Symbol
SCNI on Nasdaq
Location
Jerusalem, Israel
Fiscal year end
31 December
Latest financial report
20-F - Q4 2024 - 07 May 2025

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3,411,983,584 shares +83.7%
Common Stock, Shares, Outstanding 6,056,623,584 shares +80.8%
Weighted Average Number of Shares Outstanding, Basic 1,351,850,046 shares +81%
Weighted Average Number of Shares Outstanding, Diluted 1,351,850,046 shares +81%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1,454,000 USD -26.3%
General and Administrative Expense 1,141,000 USD -11.5%
Operating Income (Loss) -2,595,000 USD +20.5%
Nonoperating Income (Expense) -1,167,000 USD -5.2%
Net Income (Loss) Attributable to Parent -3,762,000 USD -26.1%
Earnings Per Share, Basic 0 USD/shares 0%
Earnings Per Share, Diluted 0 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 989,000 USD -67.8%
Accounts Receivable, after Allowance for Credit Loss, Current 139,000 USD +16.8%
Other Assets, Current 437,000 USD +1.8%
Assets, Current 1,506,000 USD -58.8%
Property, Plant and Equipment, Net 8,497,000 USD -16.5%
Operating Lease, Right-of-Use Asset 1,837,000 USD +81.2%
Assets 11,840,000 USD -20.3%
Employee-related Liabilities, Current 254,000 USD -34.5%
Accrued Liabilities, Current 527,000 USD +14.3%
Liabilities, Current 2,120,000 USD +26.8%
Operating Lease, Liability, Noncurrent 1,566,000 USD +1.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1,740,000 USD 0%
Retained Earnings (Accumulated Deficit) -121,673,000 USD +4.1%
Stockholders' Equity Attributable to Parent 7,858,000 USD
Liabilities and Equity 11,840,000 USD -20.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3,059,000 USD -1.8%
Net Cash Provided by (Used in) Investing Activities -6,000 USD +98.8%
Common Stock, Shares Authorized 40,000,000,000 shares +100%
Common Stock, Shares, Issued 6,056,623,584 shares +80.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3,289,000 USD -65.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1,131,000 USD -64.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 725,000 USD
Deferred Tax Assets, Valuation Allowance 23,699,000 USD -10.3%
Operating Lease, Liability 1,826,000 USD
Payments to Acquire Property, Plant, and Equipment 6,000 USD -98.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3,611,000 USD
Lessee, Operating Lease, Liability, to be Paid 3,113,000 USD
Property, Plant and Equipment, Gross 13,645,000 USD +1.2%
Operating Lease, Liability, Current 497,000 USD +36.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 384,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One 426,000 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1,287,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 384,000 USD
Deferred Tax Assets, Operating Loss Carryforwards 23,377,000 USD -10.5%
Preferred Stock, Shares Issued 1,000 shares
Preferred Stock, Shares Authorized 1,000 shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 384,000 USD
Additional Paid in Capital 125,644,000 USD +3.6%
Preferred Stock, Shares Outstanding 1,000 shares
Depreciation, Depletion and Amortization 138,000 USD +3%
Deferred Tax Assets, Net of Valuation Allowance 23,415,000 USD -10.6%
Share-based Payment Arrangement, Expense 252,000 USD -48%